MS200527-0082: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety

April 07, 2021
https://clinicaltrials.gov/ct2/show/NCT04338061
Multiple Sclerosis
Principal Investigator: Mirela Cerghet, MD
Multiple Sclerosis, Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
Accepting Participants
313-916-1482